{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:11:06Z","timestamp":1730434266956,"version":"3.28.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To better develop N-[4-(benzoylamino)phenylsulfonyl]glycine (BAPSG), a potent and selective aldose reductase inhibitor capable of delaying the progression of ocular diabetic complications, the objective of this study was to assess its pharmacokinetics. The plasma pharmacokinetics of BASPG was assessed in male Sprague-Dawley rats following intravenous, intraperitoneal and oral routes of administration and its distribution to various tissues including those of the eye was studied following intraperitoneal administration. In addition, rat plasma protein binding of BAPSG was studied using ultracentrifugation method and its ocular tissue disposition was assessed following topical administration in rabbits. Plasma and tissue levels of BAPSG were analysed using an HPLC assay. BAPSG exhibited dose-proportionate AUC0\u2192\u221e (area under the plasma concentration-time curve) following both intravenous and intraperitoneal administration over the dose range (5\u201350 mg kg\u22121) studied and an erratic oral absorption profile with low oral bioavailability. The fraction bioavailability following oral and intraperitoneal administration was 0.06 and 0.7\u20131, respectively. BAPSG exhibited short plasma elimination half-lives in the range 0.5\u20131.5 h. BAPSG was bound to rat plasma proteins and the percent protein binding ranged from 83 to 99.8%. BAPSG was better distributed to cornea, lens and retina than to brain, following intraperitoneal administration in rats. However, the distribution was lower compared with kidney and liver. Following topical administration in rabbits, BAPSG delivery to the surface ocular tissues, cornea and conjunctiva was higher compared with intraocular tissues, aqueous humour, iris-ciliary body and lens. Thus, BAPSG was distributed to ocular tissues following systemic and topical modes of administration.<\/jats:p>","DOI":"10.1211\/0022357022908","type":"journal-article","created":{"date-parts":[[2004,3,2]],"date-time":"2004-03-02T22:32:25Z","timestamp":1078266745000},"page":"351-358","source":"Crossref","is-referenced-by-count":4,"title":["Systemic and ocular pharmacokinetics of <i>N<\/i>-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor"],"prefix":"10.1093","volume":"56","author":[{"given":"Gangadhar","family":"Sunkara","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Nebraska Medical Center , Omaha, NE 68198\u20136025,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya P","family":"Ayalasomayajula","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Nebraska Medical Center , Omaha, NE 68198\u20136025,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheruku S","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Nebraska Medical Center , Omaha, NE 68198\u20136025,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L","family":"Vennerstrom","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Nebraska Medical Center , Omaha, NE 68198\u20136025,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday B","family":"Kompella","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Nebraska Medical Center , Omaha, NE 68198\u20136025,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"DeRuiter","sequence":"additional","affiliation":[{"name":"Department of Pharmacal Sciences, Auburn University , Auburn, AL 36849,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday B","family":"Kompella","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Nebraska Medical Center , Omaha, NE 68198\u20136025,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,3,1]]},"reference":[{"key":"2024103109401176700_cit1","first-page":"1516","article-title":"Aldose reductase localization in human retinal mural cells","volume":"24","author":"Akagi","year":"1983","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2024103109401176700_cit2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1442-9071.1998.tb01530.x","article-title":"Overview of studies on metabolic and vascular regulatory changes in early diabetic retinopathy","volume":"26","author":"Alder","year":"1998","journal-title":"Aust. N. Z. J. Ophthalmol."},{"key":"2024103109401176700_cit3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1023\/A:1011060705599","article-title":"Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor","volume":"18","author":"Aukunuru","year":"2001","journal-title":"Pharm. Res."},{"key":"2024103109401176700_cit4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1023\/A:1014438800893","article-title":"A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications","volume":"19","author":"Aukunuru","year":"2002","journal-title":"Pharm. Res."},{"key":"2024103109401176700_cit5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/eye.1993.60","article-title":"The lens in diabetes","volume":"7","author":"Bron","year":"1993","journal-title":"Eye"},{"key":"2024103109401176700_cit6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0167-4838(82)90448-4","article-title":"Comparative studies on aldose reductase from bovine, rat and human lens","volume":"708","author":"Conrad","year":"1982","journal-title":"Biochim. Biophys. Acta"},{"key":"2024103109401176700_cit7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.0.CO;2-7","article-title":"Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches","volume":"19","author":"Costantino","year":"1999","journal-title":"Med. Res. Rev."},{"key":"2024103109401176700_cit8","first-page":"563","article-title":"Corneal re-epithelialization in galactosemic rats","volume":"24","author":"Datiles","year":"1983","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2024103109401176700_cit9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/14756369309040751","article-title":"Enzyme selectivity analyses of arylsulfonylamino acid aldose reductase inhibitors","volume":"7","author":"Davis","year":"1993","journal-title":"J. Enzyme Inhib."},{"key":"2024103109401176700_cit10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/jnnp.44.11.991","article-title":"Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy- a clinical and neurophysiological study","volume":"44","author":"Fagius","year":"1981","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2024103109401176700_cit11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2337\/diab.30.6.459","article-title":"Clinical trial of an aldose reductase inhibitor in diabetic neuropathy","volume":"30","author":"Handelsman","year":"1981","journal-title":"Diabetes"},{"key":"2024103109401176700_cit12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0002-9343(85)90507-8","article-title":"Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy","volume":"79","author":"Jaspan","year":"1985","journal-title":"Am. J. Med."},{"key":"2024103109401176700_cit13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1464-5491.1992.tb01818.x","article-title":"A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy","volume":"9","author":"Krentz","year":"1992","journal-title":"Diabet. Med."},{"key":"2024103109401176700_cit14","first-page":"997","article-title":"Extracellular matrix alterations in human corneas with bullous keratopathy","volume":"37","author":"Ljubimov","year":"1996","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2024103109401176700_cit15","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1177\/44.12.8985139","article-title":"Basement membrane abnormalities in human eyes with diabetic retinopathy","volume":"44","author":"Ljubimov","year":"1996","journal-title":"J. Histochem. Cytochem."},{"key":"2024103109401176700_cit16","first-page":"14","article-title":"A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group","volume":"18","author":"Macleod","year":"1992","journal-title":"Diabetes Metab."},{"key":"2024103109401176700_cit17","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/jm00392a012","article-title":"Novel inhibitors of rat lens aldose reductase: N-[[(substituted amino)phenyl]sulfonyl] glycines","volume":"30","author":"Mayfield","year":"1987","journal-title":"J. Med. Chem."},{"key":"2024103109401176700_cit18","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1517\/13543784.8.12.2095","article-title":"Aldose reductase inhibitors: therapeutic implications for diabetic complications","volume":"8","author":"Oates","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"Suppl. 2","key":"2024103109401176700_cit19","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.2337\/diab.46.2.S82","article-title":"Aldose reductase inhibitors: the end of an era or the need for different trial designs","volume":"46","author":"Pfeifer","year":"1997","journal-title":"Diabetes"},{"key":"2024103109401176700_cit20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0026-0495(86)90195-2","article-title":"Clinical experience with sorbinil - an aldose reductase inhibitor","volume":"35","author":"Pitts","year":"1986","journal-title":"Metabolism"},{"key":"2024103109401176700_cit21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1021\/jm00396a037","article-title":"Spiro hydantoin aldose reductase inhibitors","volume":"31","author":"Sarges","year":"1988","journal-title":"J. Med. Chem."},{"key":"2024103109401176700_cit22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0006-2952(90)90490-C","article-title":"Inhibition of aldehyde reductase by aldose reductase inhibitors","volume":"40","author":"Sato","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"2024103109401176700_cit23","first-page":"13","article-title":"Transport processes in ocular epithelia","volume-title":"Ophthalmic drug delivery","author":"Sunkara","year":"2003"},{"key":"2024103109401176700_cit24","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1211\/0022357001774877","article-title":"In-vitro hydrolysis, permeability, and ocular uptake of prodrugs of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor","volume":"52","author":"Sunkara","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"key":"2024103109401176700_cit25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"2024103109401176700_cit26","first-page":"317","article-title":"Animal pharmacokinetic studies","volume-title":"Ophthalmic drug delivery systems","author":"Urtti","year":"1993"},{"key":"2024103109401176700_cit27","first-page":"21","article-title":"Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications","volume":"50","author":"Yabe-Nishimura","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"2024103109401176700_cit28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF01062109","article-title":"Statistical moments in pharmacokinetics","volume":"6","author":"Yamaoka","year":"1978","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"2024103109401176700_cit29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0006-8993(00)02628-7","article-title":"Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells","volume":"876","author":"Zhang","year":"2000","journal-title":"Brain Res."},{"key":"2024103109401176700_cit30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0168-8227(91)90054-H","article-title":"One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy","volume":"14","author":"Ziegler","year":"1991","journal-title":"Diabetes Res. Clin. Pract."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F0022357022908","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/56\/3\/351\/60260274\/0022357022908.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/56\/3\/351\/60260274\/0022357022908.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:15:31Z","timestamp":1730369731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/56\/3\/351\/6147235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2004,3,1]]},"published-print":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1211\/0022357022908","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2004,3]]},"published":{"date-parts":[[2004,3,1]]}}}